论文部分内容阅读
欧洲药品评估署(EMEA)于6月26日称，AbbottLaboratories公司的减肥药西布曲明（sibutramine，Reductil/Meridia）的益处高于风险，但仍将继续对该药进行监测。该署称其科学委员会将继续对Reductil进行审查，并随访其于2000年要求Abbott公司做的一项安全性和疗效研究。在意大利
The European Medicines Assessment Agency (EMEA) said on June 26 that Abbott Laboratories’ s weight-loss drug sibutramine (Reductil / Meridia) outweighs the benefits but will continue to monitor the drug. The agency said its scientific committee will continue to review Reductil and follow up on a safety and efficacy study it asked Abbott in 2000. in Italy